Corporate Overview

Regeneron is a leading biotechnology company that invents life-transforming medicines for people with serious diseases.

Regeneron is a leading biotechnology company that invents life-transforming medicines for people with serious diseases. Founded and led for over 30 years by physician-scientists, our unique ability to repeatedly and consistently translate science into medicine has led to nine FDA-approved treatments and numerous product candidates in development, almost all of which were homegrown in our laboratories. Our medicines and pipeline are designed to help patients with eye diseases, allergic and inflammatory diseases, cancer, cardiovascular and metabolic diseases, neurology, infectious diseases and rare diseases.

Regeneron is accelerating and improving the traditional drug development process through our proprietary *VelociSuite*® technologies, such as *VelocImmune*®, which uses a unique genetically-humanized mouse to produce optimized fully-human antibodies and bispecific antibodies, and through ambitious research initiatives such as the Regeneron Genetics Center®, which is conducting one of the largest genetics sequencing efforts in the world.

General Company Information

– Founded in 1988: Publicly traded company (NASDAQ: REGN) since 1991
– More than 9,000 employees in the U.S., UK and EU
– 2020 R&D investment of $2.7 billion

Locations

– Tarrytown, NY: Corporate and Research & Development headquarters
– Rensselaer, NY and Limerick, Ireland: Large-scale biologics Industrial Operations and Product Supply (IOPS) facilities
– Sleepy Hollow, NY, Basking Ridge, NJ, and Washington, D.C.: offices
– Dublin, Ireland and London, UK: Global business offices

Leadership Team

– **Leonard S. Schleifer, MD, PhD**
  President and Chief Executive Officer
  + Fellow, American Association for the Advancement of Science (AAAS)

– **George D. Yancopoulos, MD, PhD**
  President and Chief Scientific Officer
  + *Member, National Academy of Sciences*

– **P. Roy Vagelos, MD**
  Chairman of the Board
  + *Former Chief Executive Officer and Chairman of the Board, Merck & Co.*
  + *Member, National Academy of Sciences*

– **Board of Directors** includes two Nobel Laureates and seven members of the National Academy of Sciences

FDA-Approved & Marketed Medicines*

Arcalyst® (rilonacept) Injection for Subcutaneous Use [4]

DUPIXENT® (dupilumab) Injection 200mg · 300mg [1]

Evkeeza™ (evinacumab-dgnb) Injection [1]

EYLEA® (aflibercept) Injection [2]

Inmazeb™ (atoltivimab, maftivimab, and odesivimab – ebgn)

KEVZARA® (sarilumab) injection 150 mg | 200 mg [1]

LIBTAYO® (cemiplimab-rwlc) Injection 350 mg [1]

Praluent® (alirocumab) Injection [1]

ZALTRAP® (ziv-aflibercept) [3]

[1] In collaboration with Sanofi outside of U.S. For Praluent, in collaboration with Sanofi prior to April 2020; effective April 2020, Regeneron is solely responsible for the U.S. development and commercialization and Sanofi is solely responsible for the ex-U.S. development and commercialization of Praluent.
[2] In collaboration with Bayer outside of U.S. | [3] Marketed by Sanofi. | [4] Marketed by Kiniksa Pharmaceuticals.

Clinical Product Candidates

PHASE 1

REGN4018
MUC16 X CD3 Antibody
Cancer

REGN5093
MET X MET Antibody
Cancer

REGN5668
MUC16 x CD28 Antibody | Cancer

REGN5678
PSMA X CD28 Antibody
Cancer

REGN6569
GITR Antibody | Cancer

REGN7075
EGFR x CD28 Antibody
Cancer

REGN3767
LAG-3 Antibody | Solid tumors, advanced hematologic malignancies

ODRONEXTAMAB
CD20 X CD3 Antibody
Cancer

REGN5459
BCMA X CD3 Antibody
Cancer

REGN6490
IL-36R Antibody
Palmo-plantar pustulosis

REGN7257
IL2Rg Antibody
Aplastic anemia

ALN-HSD ⑤
HSD17B13 RNAi Therapeutic
Nonalcoholic steatohepatitis

CASIRIVIMAB+ IMDEVIMAB
SARS-CoV2 Virus Multi-Antibody Therapy
Multi-dose safety study in healthy volunteers

REGN5381
NPR1 Agonist Antibody
Heart failure

POZELIMAB + CEMDISIRAN ⑤
C5 Antibody X C5 siRNA Therapeutic
Paroxysmal nocturnal hemoglobinuria

NTLA-2001 ④
CRISPR/Cas9
Hereditary transthyretin amyloidosis with polyneuropathy

PHASE 2

AFLIBERCEPT ③
VEGF-Trap
High dose (8mg) for wet age-related macular degeneration (AMD)

CEMIPLIMAB ①
PD-1 Antibody
Basal cell carcinoma (BCC), Metastatic or locally advanced cutaneous squamous cell carcinoma (CSCC), neoadjuvant CSCC

ODRONEXTAMAB
CD20 X CD3 Antibody
B-cell non-Hodgkin lymphoma

REGN5458
BCMA X CD3 Antibody
Multiple myeloma

SARILUMAB ①
IL-6R Antibody
Polyarticular-course juvenile idiopathic arthritis, systemic juvenile idiopathic arthritis

DUPILUMAB ①
IL-4R Antibody
Peanut allergy, grass allergy

REGN1908-1909
Fel d 1 Multi-Antibody Therapy
Cat allergy

GARETOSMAB
Activin-A Antibody
Fibrodysplasia Ossificans Progressiva (FOP)

CEMDISIRAN ⑤
C5 siRNA Therapeutic
Immunoglobulin A nephropathy

POZELIMAB
C5 Antibody
CD-55 deficient protein-losing enteropathy

CASIRIVIMAB + IMDEVIMAB
SARS-CoV-2 Virus Multi-Antibody Therapy
Multi-dose safety study in non-hospitalized patients

EVINACUMAB
ANGPTL-3 Antibody
Severe hypertriglyceridemia

REGN4461
LEPR Agonist Antibody
Generalized lipodystrophy

PHASE 3

AFLIBERCEPT ③
VEGF-Trap
Retinopathy of prematurity (ROP), high-dose formulation (8mg) for wet age-related macular degeneration (AMD) and diabetic macular edema (DME)

CEMIPLIMAB ①
PD-1 Antibody
Non-small cell lung cancer (NSCLC), Cervical cancer, adjuvant cutaneous squamous cell carcinoma (CSCC)

DUPILUMAB ①
IL-4R Antibody
Atopic dermatitis in pediatric patients 6 mo.–5 y.o., hand and foot atopic dermatitis, asthma in pediatric patients 6-11 y.o., eosinophilic esophagitis in patients 6 and older, chronic obstructive pulmonary disease (COPD), bullous pemphigoid, prurigo nodularis, chronic spontaneous urticaria, allergic bronchopulmonary aspergillosis, chronic inducible urticaria, chronic sinusitis without nasal polyposis, allergic fungal rhinosinusitis

ITEPEKIMAB ①
IL-33 Antibody
COPD

REGN5713-5714-5715
Bet v 1 Multi-Antibody Therapy
Birch allergy

CASIRIVIMAB + IMDEVIMAB
SARS-CoV2 Virus Multi-Antibody Therapy
Treatment for certain hospitalized and non-hospitalized patients with COVID-19; prevention of COVID-19 in household contacts of diagnosed patients

ALIROCUMAB
PCSK9 Antibody
Heterozygous familial hypercholesterolemia (HeFH) in pediatrics

FASINUMAB ②
NGF Antibody
Osteoarthritis pain of the knee or hip

In collaboration with:
① Sanofi | ② Teva and Mitsubishi Tanabe | ③ Bayer | ④ Intellia | ⑤ Alnylam

■ Ophthalmology ■ Infectious Diseases ■ Immunology & Inflammatory Diseases ■ Oncology ■ Cardiovascular/Metabolic Diseases ■ Hematology ■ General Medicine ■ Rare Diseases ■ Pain

This graphic displays pipeline drug candidates currently undergoing clinical testing in a variety of diseases.
The safety and efficacy of these drug candidates have not been fully evaluated by any regulatory authorities for the indications described in this section.

Leaders in Technology

Fully human monoclonal antibodies
Regeneron has developed a suite of patented technologies (*VelociSuite®*), including *VelociGene®*, *VelocImmune®* and *VelociMab®*, that allow Regeneron scientists to determine the best targets for therapeutic intervention and rapidly generate high quality, fully human antibodies as drug candidates.

Fusion proteins
Our novel and patented "Trap" fusion protein technology creates high-affinity product candidates for many different types of signaling molecules, including growth factors and cytokines. The technology involves fusing two distinct fully human receptor components and a fully human immunoglobulin.

Regeneron Genetics Center®
A large-scale, fully-integrated genomics program that uses DNA sequencing and analysis to better understand the causes of disease, and to more rapidly and efficiently bring new therapeutics to patients in need.

Fortune: Best Companies to Work For, 2021
Science: Top Employer, 2020
Fortune: Change the World, 2020
Forbes: JUST Companies, 2020
Newsweek: America's Most Responsible Companies, 2020
Fast Company: Best Workplaces for Innovators, 2020
Dow Jones Sustainability World Index, 2020

Dow Jones Sustainability North America Index, 2020
Civic 50: Most Community-Minded Companies in the Nation, 2020
Great Places to Work: Best Workplace in Ireland, 2020
IDEA Pharma: Pharmaceutical Invention Index, 2019
Harvard Business Review: Best Performing CEOs, 2019
Shingo Institute: The Shingo Prize, 2019
Forbes: Top 10 Most Innovative Companies, 2018

To learn more about us, please visit:
REGENERON.COM 🐦 @REGENERON